Illumina Non-GAAP EPS of $0.34 beats by $0.04, revenue of $1.12B beats by $10M, lowers FY22 EPS outlook
Illumina press release (NASDAQ:ILMN): Q3 Non-GAAP EPS of $0.34  beats by $0.04.
Revenue of $1.12B (+0.9% Y/Y)  beats by $10M.
Expect full year revenue for fiscal year 2022 to be flat to 1% (from prior outlook of 4-5% vs. 4.17% consensus) higher compared to fiscal year 2021, primarily reflecting year-to-date growth in sequencing consumables revenue, largely offset by a fourth quarter decline in select research project sample volume; delayed purchases ahead of the upcoming availability of NovaSeq X and from customer inventory and capital management; and incremental foreign exchange headwinds

Expect GAAP diluted loss per share of $(26.56) to $(26.41) for fiscal year 2022, which includes goodwill impairment of $3.91 billion related to the GRAIL segment
Expect non-GAAP diluted earnings per share of $2.35 to $2.50 for fiscal year 2022 from prior outlook of $2.75-$2.90 vs $2.78 consensus